Such impressive responses have led to multiple changes in the therapeutic algorithm of advanced NSCLC, with new first-line treatment options for patients with tumors positive for PD-L1 [5], as well as combinations with CTX and second-line options after initial CTX regimens. The gene discussed is CD274; the disease is non-small cell lung carcinoma.